Progress and Prospects in Parkinson's Research/Symptoms/Azilect

AZILECT ® is prescribed as a supplement to levodopa for the treatment of Parkinson’s disease symptoms.

Active ingredients

Rasagiline is an irreversible inhibitor of monoamine oxidase^[1] used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.^[2] It is selective for MAO type B over type A by a factor of fourteen.^[3]

Inactive ingredients

Mannitol

Colloidal anhydrous silica

Maize starch

Stearic acid

Talc

Most common adverse reactions to AZILECT

Very common (Affecting more tham 1 user im 10)

Dyskinesia

Headache

Common (Affecting 1 to 10 users in 100}

abdominal pain

falls

allergy

fever

flu (influenza)

general feeling of being unwell (malaise)

neeck pain

chest pain (angina pectoris)

orthostatic hypotension

decreased appetite

constipation

dry mouth

nausea and vomiting

flatulence

leucopenia(abnormal blood tests)

arthralgia (joint pain)

musculoskeletal pain

joint inflammation (arthritis)

carpal tunnel syndrome (weakness or numbness of the hands)

decreased weight

abnormal dreams

postural instability

depression

dizziness

dystonia (muscle contractions)

rhinitis (runny nose)

dermatitis (skin irritation)

conjunctivitis (eye irritation)

urinary urgency

Less common adverse reactions to AZILECT

{Affects 1 to 10 users in 1,000)

stroke (cerebrovascular accident)

heart attack (myocardial infarction)

blistering rash (vesiculobullous rash)

Drug interactions

AZILECT should not be taken concurrently with:-

monamine oxidase (MAO) inhibitors

pethidine

St. John's Wort

References

↑ Oldfield V, Keating GM, Perry CM (2007). "Rasagiline: a review of its use in the management of Parkinson's disease". Drugs 67 (12): 1725–47. PMID 17683172.
↑ Gallagher DA, Schrag A (2008). "Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease". CNS Drugs 22 (7): 563–86. doi:10.2165/00023210-200822070-00003. PMID 18547126.
↑ Binda C, Hubálek F, Li M et al. (2005). "Binding of Rasagiline-related Inhibitors to Human Monoamine Oxidases: A Kinetic and Crystallographic Analysis". Journal of Medical Chemistry 48 (26): 8148–54. doi:10.1021/jm0506266. PMID 16366596. PMC 2519603. //www.ncbi.nlm.nih.gov/pmc/articles/PMC2519603/.

[1] Oldfield V, Keating GM, Perry CM (2007). "Rasagiline: a review of its use in the management of Parkinson's disease". Drugs 67 (12): 1725–47. PMID 17683172.

[pmid18547126-2] Gallagher DA, Schrag A (2008). "Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease". CNS Drugs 22 (7): 563–86. doi:10.2165/00023210-200822070-00003. PMID 18547126.

[pmid16366596-3] Binda C, Hubálek F, Li M et al. (2005). "Binding of Rasagiline-related Inhibitors to Human Monoamine Oxidases: A Kinetic and Crystallographic Analysis". Journal of Medical Chemistry 48 (26): 8148–54. doi:10.1021/jm0506266. PMID 16366596. PMC 2519603. //www.ncbi.nlm.nih.gov/pmc/articles/PMC2519603/.

[1]

[2]

[3]